Omeros (NASDAQ:OMER) Upgraded at StockNews.com

StockNews.com upgraded shares of Omeros (NASDAQ:OMER - Free Report) from a sell rating to a hold rating in a research report sent to investors on Tuesday.

Other equities research analysts have also issued reports about the stock. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a report on Tuesday, April 1st. D. Boral Capital reiterated a "buy" rating and set a $36.00 price target on shares of Omeros in a research note on Tuesday, April 1st. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Omeros presently has an average rating of "Moderate Buy" and a consensus price target of $22.50.

Omeros Price Performance

NASDAQ OMER traded down $0.30 during trading on Tuesday, hitting $7.06. The company's stock had a trading volume of 802,194 shares, compared to its average volume of 552,480. Omeros has a fifty-two week low of $2.97 and a fifty-two week high of $13.60. The company has a market cap of $409.93 million, a PE ratio of -3.06 and a beta of 2.35. The business's 50 day simple moving average is $8.56 and its 200-day simple moving average is $7.65.

Omeros (NASDAQ:OMER - Get Free Report) last announced its quarterly earnings data on Monday, March 31st. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.08. During the same quarter in the previous year, the business earned ($0.15) earnings per share. Analysts expect that Omeros will post -3.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Omeros

Hedge funds have recently added to or reduced their stakes in the business. Barclays PLC lifted its holdings in shares of Omeros by 121.3% in the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company's stock valued at $376,000 after buying an additional 51,873 shares during the period. State Street Corp lifted its holdings in Omeros by 0.3% in the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company's stock valued at $4,867,000 after acquiring an additional 3,839 shares during the period. HighTower Advisors LLC lifted its holdings in Omeros by 7.2% in the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company's stock valued at $235,000 after acquiring an additional 4,000 shares during the period. Quantbot Technologies LP purchased a new stake in Omeros in the 4th quarter worth approximately $46,000. Finally, Wellington Management Group LLP purchased a new position in shares of Omeros during the 3rd quarter valued at approximately $305,000. 48.79% of the stock is owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.